

Genetic interpretation of rare diseases: from mutation to patient

6-7 July 2017.

Salón de Actos

BioCruces. Hospital Universitario Cruces.

Plaza de Cruces 12, 48903. Barakaldo, Bizkaia (País Vasco)

July 6th

16:00-16:30h. Welcome address

Mª Luz del Valle (Managing Director, BioCruces)

Juana Mª Sáenz (Delegada FEDER País Vasco)

Javier Sancho (Pirepred Coordinator, BIFI, University of Zaragoza)

Juan Fernández-Recio (Scientific organizer, IBMB-CSIC, Barcelona Supercomputing Center)

July 6th

July 7th

SESSION 1:

GENETIC BASIS OF RARE DISEASES: MUTATION, ANALYSIS AND PREDICTION

Chairman: Xavier de la Cruz (VHIR)

16:30-17:30h. The genomic and biological landscape of rare and undiagnosed diseases.

Francesc Palau (Hospital Sant Joan de Deu).

17:30-18:00h. From measuring mutation impact to diagnostics yield: the path of translational research.

Xavier de la Cruz (VHIR).

18:00-18:30 h. Coffee break

18:30-19:00h. Computerization of Newborn Screening: Process and Procedures.

Tomás A. Pérez Fernández (UPV-EHU)

19:00-19:30h. Improving the newborn screening programs in Spain through the application of next generation sequencing.

Jairo Rodríguez (QGML).

19:30-19:45. Reporting mutation impact: encoding complex information to simplify clinical decisions.

Elena Álvarez (VHIR).

19:45-20:15. Genetic Bases of Rare Diabetes.

Luis Castaño. (BioCruces, Hospital Universitario Cruces, UPV/EHU, CIBERDEM, CIBERER).

SESSION 2:

INTERPRETING MUTATIONS AT MOLECULAR LEVEL: TOWARDS IMPROVED DIAGNOSIS AND THERAPEUTICS

Chairman: Olivier Cuvillier (IPBS)

9:30-10:20h. Pharmacological chaperones as a novel therapeutic intervention line for congenital erythropoietic porphyria.

Oscar Millet (CIC-BioGUNE).

10:20-10:40h. Neonatal screening in France and new variants responsible for familial congenital hypothyroidism.

Frédérique Savagner / Isabelle Olivier (CHU Toulouse).

10:40-11:00h. Expanded newborn screening for metabolic disorders: experience in Aragon.

Inmaculada García (Hospital Miguel Servet).

11:00-11:20h. Mutations in proteins: MD for diagnostics and chaperones for therapy.

Javier Sancho (BIFI. Univ. Zaragoza).

11:20-12:00h. Coffee break

12:00-12:20. Structural modeling of pathological mutations involved in protein interactions.

Juan Fernández-Recio (CSIC,BSC)

12:20-12:45. In cellulo studies of new chemical drugs on PAH activity.

Marie-Lise Maddelein (IPBS).

12:45-13:00. The performance of standard pathogenicity predictors in metabolic disease.

Josu Aguirre (VHIR).

13:00-13:15:.. Strategies for MD simulation of reported mutations.

Juan José Galano (Univ. Zaragoza).

July 7th

13:15-13:30 h. Closing remarks

Juan Fernández-Recio (Scientific organizer, IBMB-CSIC, Barcelona Supercomputing Center)